Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2023-04-27 Annual Report
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
Rapports financiers et d'audit annuels / Rapport financier annuel
Annual Report Classification · 1% confidence The document is a comprehensive 'Rapport Annuel' (Annual Report) for the fiscal year ending December 31, 2022. It contains the management report, corporate governance report, financial statements, and auditor reports. It is a full-length document (indicated by the metadata length) and serves as the primary annual disclosure for the company, fitting the definition of a 10-K (Annual Report). FY 2022
2023-04-27 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document explicitly announces the company's "2022 full-year results" and provides detailed financial tables covering the full year 2022, along with commentary from management. This content strongly aligns with the characteristics of a comprehensive annual financial disclosure. Although it mentions the full annual financial report will be made available later (suggesting an RPA might be involved for the formal filing), the document itself contains the core financial results and management discussion for the year. This makes it an Earnings Release (ER) or potentially a preliminary Annual Report disclosure. Since it covers the *full year* results and includes detailed performance metrics, it is more substantial than a typical quarterly ER. However, it also includes Q1 2023 revenue, which is unusual for a definitive 10-K. Given the comprehensive nature of the 2022 results presentation, it functions as the primary release of annual performance data. In many contexts, the initial release of full-year results, especially when combined with a brief outlook or subsequent period data, is classified as an Earnings Release (ER) if it is not the formal 10-K filing itself. Since it is a detailed announcement of annual results, it fits best under ER, as it is the initial public disclosure of the full-year performance summary, rather than the formal regulatory 10-K document itself. It is not a Call Transcript (CT) or a formal Audit Report (AR). It is the announcement of the results, making ER the most appropriate fit over 10-K. FY 2022
2023-04-12 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "Theradiag annonce ses résultats annuels 2022 et son chiffre d'affaires du premier trimestre 2023" (Theradiag announces its 2022 annual results and Q1 2023 revenue). It contains detailed financial tables for the full year 2022 (revenue, operating income, net income) and commentary on the business performance for that year, alongside a brief update on Q1 2023 revenue. This structure—a comprehensive review of the past fiscal year's performance, including key financial metrics and management commentary—is characteristic of an Earnings Release (ER) or a preliminary announcement preceding the full Annual Report (10-K). Since it focuses on announcing the results (key highlights and tables) rather than being the full, audited statutory report, 'ER' (Earnings Release) is the most appropriate classification. It is not the full 10-K, nor is it a mere announcement of a report (RPA), as it contains the actual results. It also mentions the upcoming Annual General Meeting (AGM) date, but the primary content is the financial results announcement. FY 2022
2023-04-12 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Déclaration du nombre d'actions et des droits de vote au 31 mars 2023" (Declaration of the number of shares and voting rights as of March 31, 2023). It explicitly references Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulation, which mandate the publication of the total number of shares and theoretical voting rights on specific dates. This content directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes or related statutory disclosures on voting rights.
2023-04-04 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a short announcement (2779 characters) detailing the company's 'New 2023 Financial Agenda,' which includes dates for the release of 2022 Full-Year Results, Q1 2023 Revenue, the Annual General Meeting, and subsequent quarterly updates. Since this document is an announcement about the *timing* of future reports and events, rather than the reports themselves (like a 10-K or an ER), it fits the definition of a Report Publication Announcement (RPA). It specifically announces when results and the AGM will occur, which aligns with the RPA description: 'Announcement regarding the timing, release, or publication of company reports.'
2023-03-29 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Nouvel agenda financier 2023" (New financial agenda 2023) and explicitly lists future dates for key corporate events such as the release of annual results, AGM, and quarterly revenue updates. It is an announcement detailing *when* future reports and meetings will occur, rather than being the report itself (like a 10-K or ER). Since it announces the timing of report publications, it fits the definition of a Report Publication Announcement (RPA). The document length (2944 chars) is also short, supporting the 'announcement' classification over the full report classification.
2023-03-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.